INmune Bio reports press release available

Reuters2026/07/20 11:05

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

INmune Bio disclosed completion of a commercial manufacturing milestone for its CORDStrom platform, supporting planned global registration filings.
First commercial-ready umbilical cord tissue was processed at the UK Cell and Gene Therapy Catapult under an agreement with Anthony Nolan.
Manufacturing is positioned to support a planned Phase 3 confirmation trial for Ebstrocel in RDEB, targeting US, EU, UK submissions.
Update cited alignment with the MHRA draft rare disease therapies regulatory framework; consultation link: https://www.gov.uk/government/consultations/draft-rare-disease-therapies-regulatory-framework.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200700PRIMZONEFULLFEED9764091) on July 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

INmune Bio reports press release available

You may also like

Crypto prices